How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14%

Group 1: Company Overview - Aligos Therapeutics, Inc. (ALGS) closed at $14.48, with a 5.3% gain over the past four weeks, indicating potential upside based on Wall Street analysts' short-term price targets [1] - The mean price target is $108.33, suggesting a 648.1% upside potential, with the lowest estimate at $75 (418% increase) and the highest at $175 (1108.6% increase) [1] Group 2: Analyst Insights - Analysts show strong agreement on ALGS's ability to report better earnings, with a positive trend in earnings estimate revisions, which is a strong indicator of potential upside [2][5] - The Zacks Consensus Estimate for the current year has increased by 63.7% over the past month, with no negative revisions, indicating a positive outlook for the company's earnings [5] Group 3: Price Target Considerations - While price targets are often sought after, their reliability is questioned, as they can mislead investors more often than guide them accurately [3][4] - A low standard deviation among price targets indicates high agreement among analysts regarding the stock's price movement direction, serving as a starting point for further research [4]